175 related articles for article (PubMed ID: 15126879)
1. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.
Miyake H; Eto H; Hara I; So A; Li D; Gleave ME
J Urol; 2004 Jun; 171(6 Pt 1):2477-81. PubMed ID: 15126879
[TBL] [Abstract][Full Text] [Related]
2. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Hara I; Kamidono S; Gleave ME
Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
[TBL] [Abstract][Full Text] [Related]
4. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Muramaki M; Miyake H; Hara I; Kawabata G; Kamidono S
J Urol; 2004 Oct; 172(4 Pt 1):1485-9. PubMed ID: 15371876
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Yamanaka K; Gleave ME; Hara I; Muramaki M; Miyake H
Mol Cancer Ther; 2005 Feb; 4(2):187-95. PubMed ID: 15713890
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
Muramaki M; So A; Hayashi N; Sowery R; Miyake H; Fujisawa M; Gleave ME
BJU Int; 2009 Feb; 103(3):384-90. PubMed ID: 19007378
[TBL] [Abstract][Full Text] [Related]
8. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells.
Behnsawy HM; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):843-8. PubMed ID: 21889367
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
July LV; Beraldi E; So A; Fazli L; Evans K; English JC; Gleave ME
Mol Cancer Ther; 2004 Mar; 3(3):223-32. PubMed ID: 15026542
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
[TBL] [Abstract][Full Text] [Related]
13. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
15. Clusterin confers gemcitabine resistance in pancreatic cancer.
Chen Q; Wang Z; Zhang K; Liu X; Cao W; Zhang L; Zhang S; Yan B; Wang Y; Xia C
World J Surg Oncol; 2011 May; 9():59. PubMed ID: 21609464
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]